ClinicalTrials.gg
CompletedNCT00853957AACESSUpdated Apr 30, 2012Results posted

Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension

A Phase 4 interventional study of Aliskiren/Amlodipine and Amlodipine in Hypertension, sponsored by Novartis. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-04-30.

Sponsored by Novartis · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
443
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 89 studies testing aliskiren in Hypertension — none open to participants now, none under way, none of them phase 3. aliskiren · Hypertension.

Enrollment
36th of 89
443 · median 253
Started
2009
with 12 others
Phase 4
34 of 89
none open now
Registered
54th of 89
by date
Lead sponsor
52 of 89
Novartis

Among the 89 studies testing aliskiren in Hypertension, this one is the 36th largest by enrollment, is one of 13 that started in 2009, is one of 34 in phase 4, and was the 54th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 89 studies testing aliskiren in Hypertension is open now. The open studies under Hypertension, anywhere →

About aliskiren

aliskiren: first FDA approval 2007 (TEKTURNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 89 studies testing aliskiren in Hypertension as a file.
02

Study summary

The purpose of the study is to evaluate the BP-lowering efficacy of the combination of aliskiren and amlodipine, as initial therapy, compared to amlodipine monotherapy in African American patients with Stage II hypertension.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Hypertension
  • African Americans
  • Aliskiren
  • Amlodipine
  • Systolic blood pressure
  • Diastolic blood pressure
  • Stage II
  • Combination
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women of African American background; self identified
  • Patients with stage 2 hypertension defined as MSSBP ≥ 160 mmHg and \< 200 mmHg at Visit 5 (randomization

Exclusion criteria

Exclusion Criteria:

  • Office blood pressure measured by cuff (MSDBP ≥ 110 mmHg and/or MSSBP ≥ 200 mmHg)
  • Patients on 4 or more antihypertensive medications.
  • Patients with uncontrolled hypertension (MSSBP >180 mmHg) taking more than 1 antihypertensive medication at Visit 1
  • hypertension, defined as, unresponsive to triple drug therapy at the maximum dose of each drug, one of which must be a diuretic, and not at blood pressure goal (140/90 mmHg). Therapy with a fixed dose combination of two active substances represent two drugs.
  • History of of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or .
  • Evidence of a secondary form of hypertension, including but not limited to any of the following:

    • coarctation of the aorta
    • hyperaldosteronism
    • unilateral or bilateral renal artery stenosis
    • Cushing's disease
    • polycystic kidney disease
    • pheochromocytoma
  • Known Keith-Wagener grade III or IV hypertensive retinopathy.
  • History of angioedema due to usage of an ARB or ACE inhibitor.
  • History of hypertensive encephalopathy, cerebrovascular accident, , heart failure ( Class II-IV), coronary bypass graft surgery (CABG), percutaneous coronary intervention (PCI), unstable angina pectoris, or myocardial infarction in the last 12 months

Other protocol defined inclusion/exclusion criteria applied

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
443 participants (actual)

Study arms

  • Experimental
    Aliskiren/Amlodipine

    Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg

    Drug: Aliskiren/Amlodipine

  • Active comparator
    Amlodipine

    Amlodipine 5mg titrated to 10 mg

    Drug: Amlodipine

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)

    To compare the change from baseline in mean sitting systolic blood pressure (msSBP) after 8 weeks of treatment with a combination of aliskiren and amlodipine treatment regimen (150/5 mg, 300/10 mg) versus an amlodipine treatment regimen (5 mg, 10 mg) in African American patients with Stage 2 hypertension.

    Time frame: Baseline, 8 weeks

Secondary outcomes

  1. Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)

    To compare the change from baseline in mean sitting diastolic blood pressure (msDBP) after 8 weeks of treatment with a combination of aliskiren and amlodipine treatment regimen (150/5 mg, 300/10 mg) versus an amlodipine treatment regimen (5 mg, 10 mg).

    Time frame: Baseline, 8 weeks

  2. Percentage of Patients Achieving Blood Pressure (BP) Control (<140/90 mmHg)

    Cumulative percentage of patients achieving BP control (\<140/90 mmHg)for both treatment arms was calculated. Cumulative refers to achieving blood pressure control before or at the corresponding visit. If achieving blood pressure control occurred more than once, only the first occurrence was counted.

    Time frame: 8 weeks

  3. Percentage of Responders (Patients With MSSBP < 140 mmHg or Decrease From Baseline of Greater Than or Equal to 20 mmHg)

    Cumulative percentage of responders (Responders are defined as patients with MSSBP \<140 mmHg or a decrease from baseline ≥20 mmHg) during 8 weeks of treatment was calculated. Cumulative refers to achieving blood pressure control before or at the corresponding visit. If achieving blood pressure control occurred more than once, only the first occurrence was counted.

    Time frame: 8 weeks

  4. Change From Baseline in MSSBP at Week 1 and 4

    Compare the change from baseline in MSSBP at week 1 and 4

    Time frame: Baseline, 1 and 4 weeks

  5. Percentage of Patients With Peripheral Edema by Visit

    Cumulative percentage of patients with peripheral edema was calculated. 'Cumulative' refers to patients with peripheral edema before or at the corresponding visit. If peripheral edema occurred more than once, only the first occurrence was counted. Peripheral edema is the swelling of tissues due to the accumulation of fluids. Peripheral edema was assessed by investigators during physical examination.

    Time frame: 8 weeks

07

Results

Posted Jan 21, 2011

Participant flow

Participant flow — Overall Study
MilestoneAliskiren/AmlodipineAmlodipine
Started220223
Completed206204
Not completed1419
Withdrew: Adverse event93
Withdrew: Unsatisfactory therapeutic effect02
Withdrew: Subject withdrew consent45
Withdrew: Lost to follow-up16
Withdrew: Protocol deviation03

Outcome measures

PrimaryChange From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)

To compare the change from baseline in mean sitting systolic blood pressure (msSBP) after 8 weeks of treatment with a combination of aliskiren and amlodipine treatment regimen (150/5 mg, 300/10 mg) versus an amlodipine treatment regimen (5 mg, 10 mg) in African American patients with Stage 2 hypertension.

Time frame:
Baseline, 8 weeks
Reported as:
Mean · mm Hg
Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)
mm HgAliskiren/AmlodipineAmlodipine
Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)-33.1 ± 14.53-27.8 ± 13.45
SecondaryChange From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)

To compare the change from baseline in mean sitting diastolic blood pressure (msDBP) after 8 weeks of treatment with a combination of aliskiren and amlodipine treatment regimen (150/5 mg, 300/10 mg) versus an amlodipine treatment regimen (5 mg, 10 mg).

Time frame:
Baseline, 8 weeks
Reported as:
Mean · mm Hg
Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)
mm HgAliskiren/AmlodipineAmlodipine
Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)-13.7 ± 9.60-10.4 ± 9.08
SecondaryPercentage of Patients Achieving Blood Pressure (BP) Control (<140/90 mmHg)

Cumulative percentage of patients achieving BP control (\<140/90 mmHg)for both treatment arms was calculated. Cumulative refers to achieving blood pressure control before or at the corresponding visit. If achieving blood pressure control occurred more than once, only the first occurrence was counted.

Time frame:
8 weeks
Reported as:
Number · Percentage of participants
Percentage of Patients Achieving Blood Pressure (BP) Control (<140/90 mmHg)
Percentage of participantsAliskiren/AmlodipineAmlodipine
Percentage of Patients Achieving Blood Pressure (BP) Control (<140/90 mmHg)71.457.4
SecondaryPercentage of Responders (Patients With MSSBP < 140 mmHg or Decrease From Baseline of Greater Than or Equal to 20 mmHg)

Cumulative percentage of responders (Responders are defined as patients with MSSBP \<140 mmHg or a decrease from baseline ≥20 mmHg) during 8 weeks of treatment was calculated. Cumulative refers to achieving blood pressure control before or at the corresponding visit. If achieving blood pressure control occurred more than once, only the first occurrence was counted.

Time frame:
8 weeks
Reported as:
Number · Percentage of participants
Percentage of Responders (Patients With MSSBP < 140 mmHg or Decrease From Baseline of Greater Than or Equal to 20 mmHg)
Percentage of participantsAliskiren/AmlodipineAmlodipine
Percentage of Responders (Patients With MSSBP < 140 mmHg or Decrease From Baseline of Greater Than or Equal to 20 mmHg)92.386.5
SecondaryChange From Baseline in MSSBP at Week 1 and 4

Compare the change from baseline in MSSBP at week 1 and 4

Time frame:
Baseline, 1 and 4 weeks
Reported as:
Mean · mm Hg
Change From Baseline in MSSBP at Week 1 and 4
mm HgAliskiren/AmlodipineAmlodipine
Baseline to Week 1-20.5 ± 12.53-18.2 ± 13.01
baseline to Week 4-30.9 ± 13.30-27.3 ± 13.58
SecondaryPercentage of Patients With Peripheral Edema by Visit

Cumulative percentage of patients with peripheral edema was calculated. 'Cumulative' refers to patients with peripheral edema before or at the corresponding visit. If peripheral edema occurred more than once, only the first occurrence was counted. Peripheral edema is the swelling of tissues due to the accumulation of fluids. Peripheral edema was assessed by investigators during physical examination.

Time frame:
8 weeks
Reported as:
Number · Percentage of participants
Percentage of Patients With Peripheral Edema by Visit
Percentage of participantsAliskiren/AmlodipineAmlodipine
Week 11.41.3
Week 44.15.8
Week 86.88.5

Adverse events

Collected over 8 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aliskiren/Amlodipine—1/220 (0.5%)25/220 (11.4%)
Amlodipine—1/223 (0.4%)31/223 (13.9%)
Most frequent serious events
Most frequent serious events
EventAliskiren/AmlodipineAmlodipine
Angina unstableCardiac disorders1/2200/223
PneumoniaInfections and infestations0/2201/223
Back painMusculoskeletal and connective tissue disorders0/2201/223
Most frequent other events
Most frequent other events
EventAliskiren/AmlodipineAmlodipine
Oedema peripheralGeneral disorders17/22020/223
HeadacheNervous system disorders8/22012/223

Baseline characteristics

Age Continuous
Age Continuous(years)Aliskiren/AmlodipineAmlodipineTotal
Mean53.2 ± 9.3352.4 ± 10.5752.8 ± 9.97
Age, Customized
Age, Customized(participants)Aliskiren/AmlodipineAmlodipineTotal
<55 years123127250
≥55 years9796193
Sex: Female, Male
Sex: Female, Male(Participants)Aliskiren/AmlodipineAmlodipineTotal
Female123115238
Male97108205
08

Study locations

9 sites
  • Investigative Site
    Chicago, Illinois, United States
  • Investigative Site
    Baltimore, Maryland, United States
  • Investigative Site
    Oxon Hill, Maryland, United States
  • Investigative Site
    Detroit, Michigan, United States
  • Investigative Site
    Trenton, New Jersey, United States
  • Investigative Site
    Brooklyn, New York, United States
  • Investigative Site
    Springfield Gardens, New York, United States
  • Investigative Site
    Philadelphia, Pennsylvania, United States
  • Investigative Site
    Milwaukeee, Wisconsin, United States
09

References and documents

Publications

  • Weinberger MH, Izzo JL Jr, Purkayastha D, Weitzman R, Black HR. Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension and obesity or metabolic syndrome. J Am Soc Hypertens. 2011 Nov-Dec;5(6):489-97. doi: 10.1016/j.jash.2011.08.005. Epub 2011 Sep 17. PubMed 21925996 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2009, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2011, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2009
First posted
Mar 2, 2009
Start
Feb 2009
Primary completionActual
Aug 2009
CompletionActual
Aug 2009
Results first posted
Jan 21, 2011
Last update
Apr 30, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00853957
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Mar 2, 2009
Start date
Feb 2009
Primary completion
Aug 2009
Completion
Aug 2009
Results posted
Jan 21, 2011
Last update
Apr 30, 2012

Study contacts

Novartis
study director · Novartis

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aliskiren · Amlodipine

Start the discussion